DDrare: Database of Drug Development for Rare Diseases

331. 特発性多中心性キャッスルマン病
［臨床試験数：30，薬物数：44（DrugBank：23），標的遺伝子数：30，標的パスウェイ数：148］

Searched query = "Idiopathic multicentric castleman disease", "Castleman disease"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Drug = Best Supportive Care (BSC); Bevacizumab; Bortezomib; CNTO 328; CNTO328; CX-4945 oral formulation; Cetuximab; Chimeric murine human anti-IL-6 monoclonal antibody; Cyclophosphamide; Dexamethason; Doxorubicin; Doxorubicin Hydrochloride; Etoposide; Filgrastim; Filgrastim (G-CSF); G-CSF; Hyaluronidase; Interferon-alpha; Liposomal Doxorubicin; Methotrexate; Nelfinavir; Other: Laboratory Biomarker Analysis; Other: Observation Only; Other: Pharmacological Study; Pomalidomide; Prednisone; Rituximab; Rituximab or Rituximab Hyaluronidase Human; RoActemra; SILTUXIMAB; Siltuximab; Sirolimus; Suramin; Temsirolimus; Thalidomide; Thalidomide, cyclophosphamide and prednisone; Tocilizumab; Tocilizumab [RoActemra/Actemra]; Valganciclovir; Valganciclovir (VGC); Valproic Acid; Valproic acid; Vincristine; Zidovudine

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT00891280 (ClinicalTrials.gov)	February 2009	29/4/2009	Dose-escalation Study of Oral CX-4945	A Phase 1, Multi-Center, Open-Label, Dose-Escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of CX-4945 Administered Orally to Patients With Advanced Solid Tumors, Castleman's Disease or Multiple Myeloma	Advanced Solid Tumors;Breast Cancer;Inflammatory Breast Cancer;Castleman's Disease;Multiple Myeloma	Drug: CX-4945 oral formulation	Cylene Pharmaceuticals	NULL	Recruiting	18 Years	N/A	Both	55	Phase 1	United States

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

NCT00891280
(ClinicalTrials.gov)

February 2009

29/4/2009

Dose-escalation Study of Oral CX-4945

A Phase 1, Multi-Center, Open-Label, Dose-Escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of CX-4945 Administered Orally to Patients With Advanced Solid Tumors, Castleman's Disease or Multiple Myeloma

Advanced Solid Tumors;Breast Cancer;Inflammatory Breast Cancer;Castleman's Disease;Multiple Myeloma

Drug: CX-4945 oral formulation

Cylene Pharmaceuticals

NULL

Recruiting

18 Years

N/A

Both

Phase 1

United States